KT-579 Potently Degrades at Low Oral Doses in NHP with an
Excellent Safety Profile
                                                                            IRF5 Degradation in NHP Blood Post 7 Days
                                                                                    of KT-579 QD Oral Dosing
                                                                       0




                                        IRF5 % Change from Baseline
• KT-579 potently degrades IRF5
  across multiple preclinical species
  with low oral doses
                                                                      -50




                                           24hrs After Last Dose
• KT-579 completed non-GLP
  toxicity studies in NHP and rodents
  with no adverse effects at up to                                             82%
  200-fold predicted human                                                                90%
  efficacious exposure                                                                              95%        97%
                                                               -100
                                                                              1 mg/kg   5 mg/kg   10 mg/kg   30 mg/kg



                                                                                                                        49
